RedFlag Index™ · #1 of 10 · NYSE: CVS

CVS Health Corporation: enforcement record and regulatory exposure

CVS Health Corporation scores 87 out of 100 on the RedFlag Index™ (November 2026), ranking #1 of ten tracked companies, with 9 documented cases of which 5 remain open.

December 2025: CVS paid $37.76 million under the False Claims Act for over-dispensing insulin pens, and admitted certain conduct.

2025: Omnicare, a CVS Health subsidiary, was hit with a $948.8 million judgment after a jury found more than 3.3 million false claims from 2010 to 2018.

December 2024: The DOJ sued CVS, alleging unlawful opioid dispensing since October 2013. The case is pending.

2022–2023: CVS agreed to pay about $5 billion over 10 years in the national opioid settlement.

2022: CVS paid Florida $484 million in a separate opioid settlement.

2020: Omnicare, a CVS Health subsidiary, paid $15.3 million for Controlled Substances Act violations.

DateMatterAmountStatus
October 30, 2026Oklahoma Caremark settlement over pharmacy transaction fees$2.1mResolved
October 13, 2026DOJ Controlled Substances Act and FCA dispensing case, settled with DEA compliance agreement$315mResolved, order in force
October 9, 2026Pennsylvania AG insulin pricing suitOpen
July 14, 2026FTC insulin rebating consent order (Caremark, Zinc)No penaltyResolved, order in force
January 15, 2026Missouri AG insulin pricing suitOpen
January 7, 2026Oregon AG insulin pricing suit ($900m sought)Open
December 2025Insulin-pen over-dispensing FCA settlement with admissions and CIA$37.8mResolved, order in force
August 2025Caremark Medicare Part D FCA judgment (Behnke), on appeal$289.9mOn appeal
July 2025Omnicare FCA jury verdict and judgment; Chapter 11 filing; $440m resolution proposed$948.8mJudgment
October 2024Texas AG insulin pricing suitOpen
September 2024Oak Street Health FCA kickback settlement$60mResolved
December 2022National opioid settlement (about $5bn over ten years)$5bnResolved, order in force
2022Florida opioid settlement$484mResolved
2020Omnicare Controlled Substances Act settlement$15.3mResolved

Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.

  1. State Enforcement

    Oklahoma to pay out $2.1 million from third CVS Caremark settlement over pharmacy fees

    Oklahoma will distribute more than $2.1 million in fines from a settlement with CVS Caremark over transaction fees it allegedly charged pharmacies in violation of state law. It is the state's third Caremark settlement, taking the total returned to pharmacies above $7 million.

  2. PBM Oversight

    House Oversight chair investigates whether PBMs used audits to punish pharmacies that backed reform

    Chairman James Comer asked CVS Caremark, Express Scripts and Optum Rx for documents and briefings after independent pharmacies that supported H.R. 6610 reported a surge of burdensome audits. The companies have not been accused in any proceeding.

  3. Drug Pricing

    Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme

    Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.

  4. Controlled Substances Act

    CVS agrees to pay $315 million to settle federal opioid dispensing case

    The Justice Department announced that CVS Pharmacy will pay $315 million to resolve Controlled Substances Act and False Claims Act allegations that it filled unlawful opioid prescriptions and billed federal programs for them. CVS admitted no liability and signed a compliance agreement with the DEA.

  5. PBM Rebates

    Express Scripts settled the insulin case without paying a cent or admitting a thing.

    The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.

  6. False Claims Act

    A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.

    Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.

  7. PBM Rebates

    Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

    Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

  8. Antitrust

    Caremark wins partial dismissal while Rxeed interference claim survives

    A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.

  9. Drug Pricing

    Fruth reimbursement claims move to arbitration and Missouri federal court

    A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.

  10. PBM Rebates

    Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.

    The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.

  11. False Claims Act

    CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.

    The admission is rare. The penalty, spread over ten years of conduct across the country's largest pharmacy chain, is small.

  12. Opioid Litigation

    Kentucky's opioid case against two PBMs is going to federal court. Its allegations are still unanswered.

    A Sixth Circuit ruling settles where the case is heard. Two years after Kentucky sued, no court has tested what Express Scripts and Optum actually did.

  13. FTC Enforcement

    FTC pauses OptumRx insulin case to weigh proposed consent agreement

    The Federal Trade Commission withdrew its insulin pricing case against UnitedHealth's OptumRx and its affiliate Emisar from adjudication to consider a proposed consent agreement. The agreement has been approved by the directors of the FTC's competition and consumer protection bureaus but still requires Commission approval, and its terms have not been disclosed.

  14. Controlled Substances Act

    The Justice Department says CVS filled unlawful opioid prescriptions for over a decade. Nearly two years on, nothing is decided.

    The complaint is an allegation, and CVS denies it. It describes a company whose own pharmacists and data raised the alarm.

  15. PBM Rebates

    Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

    Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

  16. Drug Pricing

    Oregon seeks $900 million from insulin makers and PBMs over pricing

    Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.

  17. PBM Rebates

    CVS Caremark becomes second major PBM to settle FTC insulin rebating case

    The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.

  18. FTC Enforcement

    FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order

    The Federal Trade Commission settled its insulin rebating case against Express Scripts, the Cigna-owned pharmacy benefit manager. The consent order requires formulary, compensation and transparency changes that the FTC estimates will save patients up to $7 billion in out-of-pocket costs over ten years.

  19. FTC Report

    FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny

    The FTC's first interim staff report on pharmacy benefit managers found that the three largest PBMs processed nearly 80% of the 6.6 billion prescriptions dispensed in the US in 2023. The report documented vertical integration with insurers and specialty pharmacies and found PBM-affiliated pharmacies charging substantially higher prices than independents for the same drugs.